von Briesen H, Meichsner C, Andreesen R, Esser R, Schrinner E, Rübsamen-Waigmann H
Chemotherapeutisches Forschungsinstitut, Georg-Speyer-Haus, Frankfurt, FRG.
Res Virol. 1990 Mar-Apr;141(2):251-7. doi: 10.1016/0923-2516(90)90029-i.
Due to the important role of monocytes/macrophages in the pathogenesis of AIDS, potential drugs with anti-HIV activity in lymphocytes must also be effective in monocytes/macrophages. For testing the efficacy of antiviral substances, monocytes/macrophages from peripheral blood were infected, respectively, with highly replicating HIV1 and HIV2 strains, thereby providing an extremely sensitive system of testing. Azidothymidine was found to inhibit both HIV types at 0.04 microgram/ml. The polysulphated polyxylan, Hoe/Bay-946 (MW 6,000 Daltons), which acts through a different mechanism and is being tested in clinical pilot studies in Germany, was also found to be effective against HIV1 and HIV2 in macrophages at concentrations of 10-50 micrograms/ml.
由于单核细胞/巨噬细胞在艾滋病发病机制中发挥重要作用，在淋巴细胞中具有抗HIV活性的潜在药物在单核细胞/巨噬细胞中也必须有效。为了测试抗病毒物质的疗效，分别用高复制性HIV1和HIV2毒株感染外周血中的单核细胞/巨噬细胞，从而提供了一个极其敏感的测试系统。发现齐多夫定在0.04微克/毫升时可抑制两种HIV类型。多硫酸化聚木糖Hoe/Bay-946（分子量6000道尔顿）通过不同机制发挥作用，正在德国进行临床试验研究，发现在10 - 50微克/毫升的浓度下对巨噬细胞中的HIV1和HIV2也有效。
